Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous Blinatumomab in Indolent NHL
NCT02961881Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2017
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities, Dose Limiting Toxicities CTCAE Grade >= 3 and 1 more. Started Sep 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT02961881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961881.